A 940-patient real-world study confirms alectinib outperforms crizotinib in ALK-positive NSCLC, mirroring results from the landmark ALEX trial.
Jorge Nieva, MD
Advertisement
Jorge Nieva, MD, is Associate Professor of Clinical Medicine at the Keck School of Medicine of USC.
Articles by Jorge Nieva, MD
Do Clinical Trial Results Hold Up in the Real World? A New Study on ALK+ Lung Cancer Says Yes—Mostly
Real-world claims data show alectinib beats crizotinib in ALK+ NSCLC survival, urging early use of newer ALK inhibitors.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Tentative Approval to New Cabozantinib Capsule Formulation
2
In Squamous NSCLC, Cemiplimab Data Pulled the Room Away From Dual Checkpoint Blockade
3
FDA Clears Rituximab Biosimilar, Expanding Options for B-Cell Malignancies
4
Dr Cortés Discusses Final KEYNOTE-522 Results in Early-Stage TNBC
5